Teva Pharmaceuticals and Fosun Pharmaceuticals have entered a partnership to develop TEV-56278, an investigational anti-PD1-IL2 Attenukine therapy. Teva’s Attenukine technology introduces a new mechanism of action that may improve efficacy and reduce toxicity across various oncology indications.

Under the agreement, Fosun Pharma will receive exclusive rights to develop, manufacture, and commercialise TEV-56278 in mainland China, Hong Kong SAR, Macau SAR, Taiwan, and select Southeast Asian countries. Teva will retain these rights for the rest of the world and will also be able to use clinical data generated by Fosun Pharma globally. The collaboration is intended to accelerate clinical development of the therapy.